secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0000950170-23-000338
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx reports preliminary 2022 revenue $352-$356M; guides 2023 revenue $425-$450M
--------------------------------------------------------------------------------

- Preliminary 2022 total product revenue $352M-$356M; Crysvita territories $257M-$258M; Dojolvi $55M-$56M.
- 2023 revenue guidance $425M-$450M; Crysvita $325M-$340M; Dojolvi $65M-$75M; net cash used ops <$400M.
- Year-end 2022 cash ~$900M; non-recurring items included $90M capex, $75M GeneTx acquisition, $30M Evkeeza license.
- Pipeline: UX143 Phase 2 data mid-2023; DTX301 Phase 3 start Q1 2023; UX701 Stage 1 enrollment mid-2023; DTX401 Phase 3 data H1 2024.
- Crysvita guidance reflects 20% YoY growth; royalties from Europe and North America (starting April 2023) included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/rare-20230106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer